New Delhi: Indian Immunologicals Ltd on Tuesday said it has jointly developed an intranasal vaccine for COVID-19. The company said it has come up with a live-attenuated needle-free intra-nasal booster vaccine developed against SARS-CoV-2 using codon deoptimisation technology in collaboration with Griffith University, Australia.
“This accomplishment signifies a major step forward in our battle against COVID-19. The development of this vaccine not only highlights our dedication to innovation in public health but also demonstrates the company’s capability in adopting novel technology,” Indian Immunologicals Ltd (IIL) MD K Anand Kumar said in a statement.
By facilitating non-invasive immunisation, IIL aims to enhance vaccination rates, ultimately safeguarding more individuals and communities, he added.
As per the Hyderabad-based firm, COVID-19 is still a cause of around 1,700 deaths a week around the world.
